Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Others

Ratios

Atea Pharmaceuticals (AVIR) Gains from Sales and Divestitures (2020)

Atea Pharmaceuticals' Gains from Sales and Divestitures history spans 1 years, with the latest figure at $20000.0 for Q4 2020.

Quarterly Gains from Sales and Divestitures changed N/A to $20000.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $20000.0 through Dec 2020, changed N/A year-over-year, with the annual reading at $20000.0 for FY2020, N/A changed from the prior year.
Gains from Sales and Divestitures came in at $20000.0 for Q4 2020.
In the past five years, Gains from Sales and Divestitures ranged from a high of $20000.0 in Q4 2020 to a low of $20000.0 in Q4 2020.